$1.14
+0.03 (+2.70%)
Open$1.09
Previous Close$1.11
Day High$1.20
Day Low$1.09
52W High$3.22
52W Low$0.98
Volume—
Avg Volume202.7K
Market Cap47.23M
P/E Ratio—
EPS$-0.24
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,721.9% upside
Current
$1.14
$1.14
Target
$43.57
$43.57
$34.30
$43.57 avg
$49.66
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 211.9K | 310.6K | 9.20M |
| Net Income | -11,185,824 | -14,757,023 | -2,830,498 |
| Profit Margin | -5,271.3% | -5,007.7% | -30.8% |
| EBITDA | -11,185,824 | -15,576,858 | -2,581,372 |
| Free Cash Flow | — | — | -3,568,526 |
| Rev Growth | -31.8% | -31.8% | +9.2% |
| Debt/Equity | — | — | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |